arcalyst
(rilonacept)Kiniksa Pharmaceuticals (UK), Ltd.
Usage: ARCALYST (rilonacept) is indicated for treating Cryopyrin-Associated Periodic Syndromes (CAPS) in patients 12 years and older, maintaining remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in patients weighing at least 10 kg, and for managing recurrent pericarditis in patients 12 years and older.